- Home
- MRM vs BGLC Comparison
MRM vs BGLC Comparison
Compare MRM & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRM
- BGLC
- Stock Information
- Founded
- MRM 2000
- BGLC 2017
- Country
- MRM Japan
- BGLC Malaysia
- Employees
- MRM 1101
- BGLC N/A
- Industry
- MRM Other Consumer Services
- BGLC Medical Specialities
- Sector
- MRM Consumer Discretionary
- BGLC Health Care
- Exchange
- MRM Nasdaq
- BGLC Nasdaq
- Market Cap
- MRM 5.9M
- BGLC 5.8M
- IPO Year
- MRM 2020
- BGLC N/A
- Fundamental
- Price
- MRM $0.78
- BGLC $2.90
- Analyst Decision
- MRM
- BGLC
- Analyst Count
- MRM 0
- BGLC 0
- Target Price
- MRM N/A
- BGLC N/A
- AVG Volume (30 Days)
- MRM 4.0M
- BGLC 1.9M
- Earning Date
- MRM 01-01-0001
- BGLC 05-14-2025
- Dividend Yield
- MRM N/A
- BGLC N/A
- EPS Growth
- MRM N/A
- BGLC N/A
- EPS
- MRM N/A
- BGLC N/A
- Revenue
- MRM $44,462,062.00
- BGLC $9,510,646.00
- Revenue This Year
- MRM N/A
- BGLC N/A
- Revenue Next Year
- MRM N/A
- BGLC N/A
- P/E Ratio
- MRM N/A
- BGLC N/A
- Revenue Growth
- MRM 2.80
- BGLC N/A
- 52 Week Low
- MRM $0.34
- BGLC $2.01
- 52 Week High
- MRM $8.39
- BGLC $8.40
- Technical
- Relative Strength Index (RSI)
- MRM 52.73
- BGLC 50.40
- Support Level
- MRM $0.60
- BGLC $2.47
- Resistance Level
- MRM $0.90
- BGLC $2.92
- Average True Range (ATR)
- MRM 0.23
- BGLC 0.49
- MACD
- MRM 0.01
- BGLC 0.07
- Stochastic Oscillator
- MRM 44.69
- BGLC 54.15
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.